Goldman Sachs’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,975
| Closed | -$33.3K | – | 6700 |
|
|
2025
Q4 | $33.3K | Buy |
4,975
+3,706
| +292% | +$22K | ﹤0.01% | 6314 |
|
|
2025
Q3 | $5.57K | Sell |
1,269
-19,496
| -94% | -$92.5K | ﹤0.01% | 6272 |
|
|
2025
Q2 | $92.2K | Buy |
20,765
+6,134
| +42% | +$25.6K | ﹤0.01% | 5833 |
|
|
2025
Q1 | $82.8K | Sell |
14,631
-5,109
| -26% | -$65.4K | ﹤0.01% | 5822 |
|
|
2024
Q4 | $417K | Buy |
19,740
+2,198
| +13% | +$50.5K | ﹤0.01% | 5339 |
|
|
2024
Q3 | $472K | Buy |
17,542
+9,759
| +125% | +$287K | ﹤0.01% | 5082 |
|
|
2024
Q2 | $222K | Buy |
7,783
+3,790
| +95% | +$133K | ﹤0.01% | 5218 |
|
|
2024
Q1 | $169K | Sell |
3,993
-34
| -0.8% | -$1.53K | ﹤0.01% | 5153 |
|
|
2023
Q4 | $215K | Buy |
4,027
+989
| +33% | +$44.6K | ﹤0.01% | 5123 |
|
|
2023
Q3 | $131K | Sell |
3,038
-1,665
| -35% | -$76.8K | ﹤0.01% | 5135 |
|
|
2023
Q2 | $258K | Buy |
4,703
+994
| +27% | +$54.5K | ﹤0.01% | 5086 |
|
|
2023
Q1 | $156K | Buy |
3,709
+2,434
| +191% | +$72.2K | ﹤0.01% | 5373 |
|
|
2022
Q4 | $35.3K | Sell |
1,275
-2,439
| -66% | -$60.1K | ﹤0.01% | 5638 |
|
|
2022
Q3 | $95K | Sell |
3,714
-2,588
| -41% | -$85.6K | ﹤0.01% | 5696 |
|
|
2022
Q2 | $227K | Sell |
6,302
-3,072
| -33% | -$139K | ﹤0.01% | 5582 |
|
|
2022
Q1 | $583K | Sell |
9,374
-386
| -4% | -$22.8K | ﹤0.01% | 5211 |
|
|
2021
Q4 | $688K | Sell |
9,760
-300
| -3% | -$21.3K | ﹤0.01% | 5137 |
|
|
2021
Q3 | $702K | Sell |
10,060
-12,318
| -55% | -$980K | ﹤0.01% | 4992 |
|
|
2021
Q2 | $1.86M | Buy |
22,378
+13,545
| +153% | +$958K | ﹤0.01% | 4274 |
|
|
2021
Q1 | $483K | Sell |
8,833
-2,103
| -19% | -$102K | ﹤0.01% | 5150 |
|
|
2020
Q4 | $470K | Sell |
10,936
-156
| -1% | -$5.82K | ﹤0.01% | 4639 |
|
|
2020
Q3 | $334K | Buy |
11,092
+6,968
| +169% | +$234K | ﹤0.01% | 4679 |
|
|
2020
Q2 | $128K | Buy |
4,124
+3,021
| +274% | +$81.4K | ﹤0.01% | 4926 |
|
|
2020
Q1 | $24K | Sell |
1,103
-61
| -5% | -$1.65K | ﹤0.01% | 5117 |
|
|
2019
Q4 | $36K | Hold |
1,164
| – | – | ﹤0.01% | 5143 |
|
|
2019
Q3 | $36K | Sell |
1,164
-26,832
| -96% | -$667K | ﹤0.01% | 5072 |
|
|
2019
Q2 | $560K | Buy |
27,996
+26,643
| +1,969% | +$781K | ﹤0.01% | 4339 |
|
|
2019
Q1 | $58K | Buy |
+1,353
| New | +$49.1K | ﹤0.01% | 4987 |
|
|
2018
Q4 | – | Sell |
-2,611
| Closed | -$137K | – | 5419 |
|
|
2018
Q3 | $137K | Sell |
2,611
-4
| -0.2% | -$224 | ﹤0.01% | 5032 |
|
|
2018
Q2 | $140K | Sell |
2,615
-9,570
| -79% | -$490K | ﹤0.01% | 5110 |
|
|
2018
Q1 | $609K | Buy |
12,185
+9,998
| +457% | +$448K | ﹤0.01% | 4364 |
|
|
2017
Q4 | $72K | Sell |
2,187
-1
| -0% | -$34 | ﹤0.01% | 5839 |
|
|
2017
Q3 | $82K | Sell |
2,188
-1,055
| -33% | -$31.2K | ﹤0.01% | 6125 |
|
|
2017
Q2 | $83K | Buy |
3,243
+678
| +26% | +$16.8K | ﹤0.01% | 6199 |
|
|
2017
Q1 | $67K | Sell |
2,565
-583
| -19% | -$16.8K | ﹤0.01% | 6208 |
|
|
2016
Q4 | $96K | Buy |
3,148
+1,601
| +103% | +$40.7K | ﹤0.01% | 6162 |
|
|
2016
Q3 | $42K | Sell |
1,547
-1,623
| -51% | -$45.1K | ﹤0.01% | 6541 |
|
|
2016
Q2 | $91K | Sell |
3,170
-2,567
| -45% | -$81.6K | ﹤0.01% | 6173 |
|
|
2016
Q1 | $173K | Buy |
5,737
+4,588
| +399% | +$130K | ﹤0.01% | 5728 |
|
|
2015
Q4 | $40K | Sell |
1,149
-18,218
| -94% | -$623K | ﹤0.01% | 6644 |
|
|
2015
Q3 | $732K | Buy |
19,367
+17,546
| +964% | +$816K | ﹤0.01% | 4770 |
|
|
2015
Q2 | $104K | Sell |
1,821
-149
| -8% | -$8.48K | ﹤0.01% | 6582 |
|
|
2015
Q1 | $115K | Buy |
1,970
+302
| +18% | +$16.2K | ﹤0.01% | 6373 |
|
|
2014
Q4 | $95K | Sell |
1,668
-2,189
| -57% | -$104K | ﹤0.01% | 6589 |
|
|
2014
Q3 | $158K | Buy |
3,857
+536
| +16% | +$24.6K | ﹤0.01% | 6343 |
|
|
2014
Q2 | $151K | Buy |
+3,321
| New | +$140K | ﹤0.01% | 6383 |
|
Other funds holding HBIO
WCM
VCM
CCM
MIM
NCNMGF
Goldman Sachs's HBIO Position: Q1 2026 in Review
Goldman Sachs sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 4,975 shares — an estimated $33.3K sold.
Goldman Sachs first reported a position in HBIO in Q2 2014 and held it in 46 quarters. The position peaked at $1.86M in Q2 2021. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.
- Goldman Sachs reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
- Goldman Sachs sold 4,975 Harvard Bioscience shares in Q1 2026, an estimated $33.3K.
- Goldman Sachs first reported a position in Harvard Bioscience in Q2 2014 and held it in 46 quarters.
- Goldman Sachs's Harvard Bioscience position peaked at $1.86M in Q2 2021.
- 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.